Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6% – Here’s Why

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) traded down 6% during mid-day trading on Tuesday . The stock traded as low as $11.90 and last traded at $12.11. 317,967 shares were traded during trading, a decline of 77% from the average session volume of 1,357,926 shares. The stock had previously closed at $12.88.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Price Performance

The company’s fifty day simple moving average is $14.05 and its 200-day simple moving average is $14.50. The firm has a market capitalization of $555.64 million, a PE ratio of -11.53 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. As a group, equities research analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently made changes to their positions in CAPR. Farallon Capital Management LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at $31,056,000. Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 700,243 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at $8,693,000. Altium Capital Management LLC grew its holdings in shares of Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after buying an additional 429,000 shares during the last quarter. Finally, Black Diamond Financial LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at $3,833,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.